Discovery | Charles River

Logica brings together industry-leading wet science experience and deep AI expertise to redefine your drug discovery. We offer: • Leading-edge AI/ML • Experimental expertise, enabling predictable outcomes • Efficient screening through access to high-throughput libraries • Human insights for expert decision making • A risk-sharing model Visit our website to discover the benefits of our approach. https://okt.to/InwYOx #AI #ML #Drugdiscovery #Logica

Join us at #PEGSEurope next week in Barcelona to learn about our end-to-end antibody discovery solutions. Schedule a meeting here: https://okt.to/UJF0Pn

Logica is heading to BIO-Europe this November! Our team is excited to discuss how our AI-driven drug discovery platform can accelerate your journey from target to candidate. Don't miss this opportunity to explore how Logica can enhance your drug discovery program. Schedule a meeting with our experts to learn more about our innovative approach combining AI expertise with extensive wet lab experience. https://okt.to/25SDia #BIOEurope #AI #Logica #DrugDiscovery

We are pleased to offer a new fixed-cost HTS service, designed to enable excellent chemical starting points for PoC studies or funding-limited research: https://okt.to/36riYX

Ilona Vuist, Teamlead Trial Management, is at the EORTC-NCI-AACR Symposium (#ENASymp24) on molecular targets and cancer therapeutics, in Barcelona, Spain. Stop by to discuss our scientific poster #PB172 "Evaluation of a Novel and Highly Efficacious Anti-HER2 Antibody-Drug Conjugate for HER2-Positive Breast Cancer Treatment". In collaboration with VERAXA Biotech GmbH. Learn more, talk to an expert: https://okt.to/NA8gVt EORTC - European Organisation for Research and Treatment of Cancer

Are you aware that ~75% of anticancer drugs must be tested against pediatric cancer? 💊 It’s crucial to determine if your drug falls under this category.  The RACE Act addresses the gap in approved pediatric cancer treatments, by requiring adult oncology therapies to be tested for pediatric cancer use before FDA approval. Failure to consider the RACE Act early on could potentially disrupt progress during the IND stage. Access our 200+ well-characterized pediatric PDX models RACE Act-compliant (through ITCC-P4 consortium) to facilitate smoother transition to clinic.🚀 https://okt.to/TzGghu #PediatricCancer #RACEAct #OncologyResearch #ClinicalTrials #DrugDevelopment 

In a new Nature Communications paper, Charles River and Caltech scientists collaborated to determine the human extracellular and cell surface interactomes of natural and engineered AAVs. Using our #Retrogenix® Platform, the researchers identified new AAV interactors on human cells with potential implications for gene therapy development. Read the paper here: https://okt.to/GScybe

AI-powered #drugdiscovery is revolutionizing our industry. This cutting-edge technology is designed to accelerate timelines, enhance hit identification, and maximize success rates. To dive deeper into how #AI is changing what’s possible, visit our website.https://okt.to/bAL1i7 #AI #Logica #DrugDiscovery

Join this live webinar to learn more about micro-electro array #electrophysiology, and how it can be used to study real-time cellular activity in primary cells, iPSC-derived neurons, and ex vivo brain slices. https://okt.to/52XIHt

Learn about ADC discovery in cancer, from synthesis to safety and efficacy studies, in an on-demand webinar with Charles River experts: https://okt.to/4do1ax